Affinia Therapeutics

Affinia Therapeutics is pioneering a new type of rationally designed gene therapy for the treatment of rare and common diseases. The company’s first-in-class or best-in-class pipeline of product candidates in cardiovascular and neurological disease areas leverages its proprietary next-generation capsids, payloads, or manufacturing methods, demonstrating efficacy, safety, and differentiation in relevant animal models.